Trial Information

Summary: Malignant Melanoma Study CSTI571BUS255

Novartis Oncology is supporting a clinical study that is being sponsored and conducted by Dr. F. Stephen Hodi of the Dana-Farber Cancer Institute, to find out if the study drug imatinib mesylate (GleevecŪ) is safe and effective for people, 18 years of age or older, who have metastatic acral lentiginous melanoma which is a form of skin cancer that commonly appears as a dark patch on the palms, soles, fingers, toes, under fingernails or toenails, or mucous membranes. GleevecŪ has been approved for the treatment of certain types of cancers, however it is not approved for metastatic acral lentiginous melanoma.

Participants will be asked to visit the study center a predetermined number of times over the course of a one year period.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 27, 2008 at 1:00:35 PM